Michael A. Lyons

477 total citations
19 papers, 326 citations indexed

About

Michael A. Lyons is a scholar working on Infectious Diseases, Pharmacology and Epidemiology. According to data from OpenAlex, Michael A. Lyons has authored 19 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 6 papers in Pharmacology and 6 papers in Epidemiology. Recurrent topics in Michael A. Lyons's work include Tuberculosis Research and Epidemiology (11 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). Michael A. Lyons is often cited by papers focused on Tuberculosis Research and Epidemiology (11 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). Michael A. Lyons collaborates with scholars based in United States, Belgium and Australia. Michael A. Lyons's co-authors include Brad Reisfeld, Anne J. Lenaerts, Raymond S. H. Yang, Arthur N. Mayeno, Elizabeth J. Brooks, Matthew Zimmerman, Matthew J. Reichlen, Véronique Dartois, Eric L. Nuermberger and Brendan Prideaux and has published in prestigious journals such as Bioinformatics, Scientific Reports and Environmental Health Perspectives.

In The Last Decade

Michael A. Lyons

18 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael A. Lyons United States 9 181 106 92 61 46 19 326
Ana Ribeiro Italy 11 253 1.4× 152 1.4× 241 2.6× 17 0.3× 18 0.4× 15 458
Serena Fucile Italy 9 219 1.2× 47 0.4× 31 0.3× 78 1.3× 64 1.4× 15 366
David Pereira United States 10 47 0.3× 60 0.6× 117 1.3× 52 0.9× 104 2.3× 13 364
Krishna C. Chinta South Africa 9 169 0.9× 123 1.2× 242 2.6× 56 0.9× 6 0.1× 10 481
Yun Lan Yueh United States 8 144 0.8× 59 0.6× 62 0.7× 40 0.7× 40 0.9× 10 384
Souzan B. Yanni United States 8 153 0.8× 90 0.8× 58 0.6× 75 1.2× 10 0.2× 12 402
Xiaowei Fu United States 14 56 0.3× 65 0.6× 187 2.0× 90 1.5× 5 0.1× 22 519
Chantal Masungi Belgium 8 169 0.9× 105 1.0× 128 1.4× 36 0.6× 6 0.1× 8 503
Ricardo Nalda‐Molina Spain 11 62 0.3× 38 0.4× 102 1.1× 105 1.7× 6 0.1× 25 437

Countries citing papers authored by Michael A. Lyons

Since Specialization
Citations

This map shows the geographic impact of Michael A. Lyons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Lyons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Lyons more than expected).

Fields of papers citing papers by Michael A. Lyons

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Lyons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Lyons. The network helps show where Michael A. Lyons may publish in the future.

Co-authorship network of co-authors of Michael A. Lyons

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Lyons. A scholar is included among the top collaborators of Michael A. Lyons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Lyons. Michael A. Lyons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Lyons, Michael A., Andrés Obregón‐Henao, Karen Rossmassler, et al.. (2024). Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 68(5). e0101023–e0101023. 2 indexed citations
2.
Fontes, Fabio L., et al.. (2024). Pyrazinoic acid, the active form of the anti-tuberculosis drug pyrazinamide, and aromatic carboxylic acid analogs are protonophores. Frontiers in Molecular Biosciences. 11. 1350699–1350699. 5 indexed citations
3.
Kaya, Firat, Allison Bauman, Lisa M. Massoudi, et al.. (2023). Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model. Antimicrobial Agents and Chemotherapy. 67(11). e0059723–e0059723. 7 indexed citations
4.
Reichlen, Matthew J., Sarah E. M. Born, Michael A. Lyons, et al.. (2023). Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency. Antimicrobial Agents and Chemotherapy. 67(1). e0148322–e0148322. 2 indexed citations
5.
Kaya, Firat, Allison Bauman, Lisa M. Massoudi, et al.. (2023). Drug Distribution and Efficacy of the DprE1 Inhibitor BTZ-043 in the C3HeB/FeJ Mouse Tuberculosis Model. Zenodo (CERN European Organization for Nuclear Research).
6.
Lyons, Michael A.. (2022). Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide. Antimicrobial Agents and Chemotherapy. 66(12). e0089822–e0089822. 2 indexed citations
7.
Lyons, Michael A.. (2021). Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design. CPT Pharmacometrics & Systems Pharmacology. 10(3). 211–219. 8 indexed citations
8.
Podell, Brendan K., Chad Frank, Gregory T. Robertson, et al.. (2020). Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks. Scientific Reports. 10(1). 6047–6047. 16 indexed citations
9.
Lyons, Michael A.. (2019). Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients. Antimicrobial Agents and Chemotherapy. 63(12). 10 indexed citations
10.
Lyons, Michael A.. (2018). Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. Antimicrobial Agents and Chemotherapy. 62(7). 24 indexed citations
11.
Irwin, Scott M., Brendan Prideaux, Edward Lyon, et al.. (2016). Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice. ACS Infectious Diseases. 2(4). 251–267. 113 indexed citations
12.
Lyons, Michael A. & Anne J. Lenaerts. (2015). Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model. Journal of Pharmacokinetics and Pharmacodynamics. 42(4). 375–389. 10 indexed citations
13.
Lyons, Michael A.. (2014). Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment. Journal of Pharmacokinetics and Pharmacodynamics. 41(6). 613–623. 5 indexed citations
14.
Weijs, Liesbeth, Anthony C. Roach, Raymond S. H. Yang, et al.. (2013). Lifetime PCB 153 bioaccumulation and pharmacokinetics in pilot whales: Bayesian population PBPK modeling and Markov chain Monte Carlo simulations. Chemosphere. 94. 91–96. 11 indexed citations
15.
Lyons, Michael A., Brad Reisfeld, Raymond S. H. Yang, & Anne J. Lenaerts. (2013). A Physiologically Based Pharmacokinetic Model of Rifampin in Mice. Antimicrobial Agents and Chemotherapy. 57(4). 1763–1771. 36 indexed citations
16.
Reisfeld, Brad, et al.. (2012). DoseSim: a tool for pharmacokinetic/pharmacodynamic analysis and dose reconstruction. Bioinformatics. 29(3). 400–401. 1 indexed citations
17.
Reisfeld, Brad, et al.. (2011). A Physiologically Based Pharmacokinetic Model for Capreomycin. Antimicrobial Agents and Chemotherapy. 56(2). 926–934. 17 indexed citations
18.
Lyons, Michael A., Raymond S. H. Yang, Arthur N. Mayeno, & Brad Reisfeld. (2008). Computational Toxicology of Chloroform: Reverse Dosimetry Using Bayesian Inference, Markov Chain Monte Carlo Simulation, and Human Biomonitoring Data. Environmental Health Perspectives. 116(8). 1040–1046. 49 indexed citations
19.
Zirvi, Karimullah A., et al.. (1989). α-Difluoromethylornithine inhibits liver metastasis produced by intrasplenic injection of human tumor cells into nude mice. Clinical & Experimental Metastasis. 7(6). 591–598. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana Ribeiro Breakdown of academic impact, for papers by Serena Fucile Breakdown of academic impact, for papers by David Pereira Breakdown of academic impact, for papers by Krishna C. Chinta Breakdown of academic impact, for papers by Yun Lan Yueh Breakdown of academic impact, for papers by Souzan B. Yanni Breakdown of academic impact, for papers by Xiaowei Fu Breakdown of academic impact, for papers by Chantal Masungi Breakdown of academic impact, for papers by Ricardo Nalda‐Molina
Rankless by CCL
2026